Adalimumab is an immunosuppressive drug that neutralizes the membrane and soluble form of tumor necrosis factor alpha (TNF-α). As a representative of anti-TNF-α inhibitors, it is used in the treatment of articular psoriasis, rheumatoid arthritis, and Crohn's disease. The aim of the study was to evaluate changes in the expression of genes encoding HRH1-4 receptors in human skin keratinocytes (HaCaT line) treated with bacterial lipopolysaccharide followed by adalimumab compared to the control culture. HaCaT was exposed to 1 ng / ml LPS for 8 hours and then to 8 µg / ml adalimumab for 2, 8 and 24 hours compared to the control culture. Molecular analysis included the determination of the microarray expression profile of the assessed genes, which was then validated with the quantitative real-time polymerase chain reaction preceded by reverse transcription (RTqPCR) method. Under conditions of induced inflammation -LPS, the concentration of HRH1-3 is significantly lower compared to control and increases with the addition of the drug (p <0.05). The highest concentration of HRH1 and HRH3 in keratinocyte cultures exposed to adalimumab was observed after 8 hours of incubation. HRH2 expression is also highest under the influence of adalimumab (p<0.05). We have shown that adalimumab influences the activity of the histaminergic system in skin keratinocytes in vitro. The complex nature of the histaminergic system was confirmed.